Its primary job is to act as a cellular bodyguard, neutralizing free radicalsunstable molecules that cause damage to our cells and contribute to visible signs of aging
On April 1, 2026, the FDA approved orforglirpon under the brand name Foundayo to reduce excess body weight and maintain weight reduction long term in: Adults with obesity Adults with overweight and at least one weight-related medical condition Like other GLP-1s for weight loss, orforglipron is also indicated in combination with a reduced-calorie diet and increased physical activity
Simply search for " liquid lipo " in your preferred neighborhood, and you'll find a list of practitioners in your area
Visits are clearly priced, but they are not cheap, and medication is never included
CagriSema's REDEFINE 1 number is competitive against tirzepatide's SURMOUNT-1 figure, but a direct head-to-head trial reported in February 2026 favored tirzepatide